Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market Forecast and Outlook 2025 to 2035

The global oligonucleotide synthesis market is projected to reach USD 16.5 billion by 2035, recording an absolute increase of USD 11.79 billion over the forecast period. The market is valued at USD 4.71 billion in 2025 and is set to rise at a CAGR of 13.4% during the assessment period.

The overall market size is expected to grow by 3.5 times during the same period, supported by increasing demand from pharmaceutical therapeutic development and expanding applications in molecular diagnostics across both developed and emerging biotechnology markets.

Quick Stats for Oligonucleotide Synthesis Market

• Oligonucleotide Synthesis Market Value (2025): USD 4.71 billion
• Oligonucleotide Synthesis Market Forecast Value (2035): USD 16.5 billion
• Oligonucleotide Synthesis Market Forecast CAGR: 13.4%
• Leading Product in Oligonucleotide Synthesis Market: Services (32.6%)
• Key Growth Regions in Oligonucleotide Synthesis Market: Asia Pacific, North America, and Europe
• Top Players in Oligonucleotide Synthesis Market: Thermo Fisher Scientific, Merck KGaA, Danaher, Revvity Discovery Limited, Agilent Technologies, Inc., Bio-Synthesis, Inc., Kaneka Eurogentec S.A., LGC Biosearch Technologies, Biolegio, Twist Bioscience

Growing application diversity in gene therapy research, synthetic biology platforms, and precision medicine programs creates expanding opportunities for oligonucleotide synthesis innovation and specialized product development. Rising research output in developed nations, coupled with expanding genomics infrastructure through advanced sequencing facilities and modern synthesis technologies, further accelerate market penetration across diverse life sciences segments. The growing global demand for custom oligonucleotides, particularly in PCR primer and sequencing applications, generates sustained requirements for high-purity synthesis services and specialized reagent materials.

Technical advancements in solid-phase synthesis technologies demonstrating measurable improvements in coupling efficiency, reduced synthesis time, and quality optimization reinforce researcher confidence in oligonucleotide synthesis economics, while oligonucleotide therapeutics sector trends toward antisense drug deployment expand addressable market opportunities beyond traditional research applications into clinical therapeutic supply chains.

Pharmaceutical companies and academic institutions increasingly incorporate custom oligonucleotide services into drug development programs, diagnostic assay development, and genomic research protocols, creating mainstream consumption channels that extend beyond specialty molecular biology applications into conventional pharmaceutical development environments.

However, fluctuating raw material costs for phosphoramidite reagents and stringent regulatory requirements for therapeutic oligonucleotide manufacturing may pose challenges to market expansion. Quality control demands for pharmaceutical-grade synthesis and analytical verification requirements in certain regions also influence production capacity, requiring manufacturers to develop diversified capability strategies catering to specific purity requirements across different geographical markets.

Supply chain complexity during reagent procurement and the technical requirements for synthesis platform optimization and quality assurance may limit accessibility among smaller contract research organizations in developing regions with limited infrastructure for advanced oligonucleotide synthesis and purification capabilities.

Oligonucleotide Synthesis Market Year-over-Year Forecast 2025 to 2035

Between 2025 and 2030, the oligonucleotide synthesis market is projected to expand from USD 4.71 billion to USD 8.79 billion, resulting in a value increase of USD 4.08 billion, which represents 34.6% of the total forecast growth for the decade. This phase of development will be shaped by rising demand for therapeutic oligonucleotide development and diagnostic primer synthesis, product innovation in high-throughput synthesis platforms and modified nucleotide configurations, as well as expanding integration with CRISPR gene editing initiatives and RNA interference therapeutic platforms. Companies are establishing competitive positions through investment in large-scale synthesis technology development, pharmaceutical-grade manufacturing capabilities, and strategic market expansion across contract synthesis facilities, integrated drug development segments, and molecular diagnostics applications.

From 2030 to 2035, the market is forecast to grow from USD 8.79 billion to USD 16.5 billion, adding another USD 7.71 billion, which constitutes 65.4% of the overall ten-year expansion. This period is expected to be characterized by the expansion of specialized oligonucleotide derivatives, including targeted chemical modifications and customized sequence designs tailored for specific therapeutic applications, strategic collaborations between oligonucleotide manufacturers and pharmaceutical companies, and an enhanced focus on GMP manufacturing practices and regulatory compliance certifications. The growing emphasis on personalized medicine principles and nucleic acid therapeutic technologies will drive demand for high-performance oligonucleotide synthesis solutions across diverse pharmaceutical and diagnostic applications.

Oligonucleotide Synthesis Market Key Takeaways

Metric	Value
Market Value (2025)	USD 4.71 billion
Market Forecast Value (2035)	USD 16.5 billion
Forecast CAGR (2025-2035)	13.4%

Why is the Oligonucleotide Synthesis Market Experiencing Rapid Growth?

The oligonucleotide synthesis market grows by enabling pharmaceutical researchers, molecular biologists, and diagnostic developers to access custom nucleic acid sequences that support experimental workflows while meeting research demand for consistent quality specifications.

Molecular biologists and drug developers face mounting pressure to develop innovative therapeutic modalities with proven target specificity and nuclease resistance characteristics, with custom oligonucleotides typically providing 15-100 base length ranges and comprehensive chemical modification options essential for PCR amplification, gene silencing applications, and diagnostic probe development, making these products essential for competitive positioning in pharmaceuticals, diagnostics, and research categories.

The life sciences industry's need for reliable oligonucleotide supply and consistent synthesis quality creates demand for diverse product offerings that can provide superior sequence fidelity, maintain predictable performance across different applications, and ensure quality compliance without compromising research economics or experimental specifications.

Government initiatives promoting genomics research and precision medicine development drive adoption in pharmaceutical companies, academic research institutes, and diagnostic laboratories, where oligonucleotide selection has a direct impact on experimental success outcomes and therapeutic development progress.

The biotechnology industry's growing focus on RNA therapeutics and gene editing technologies further expands market opportunities, with pharmaceutical research demonstrating measurable therapeutic advantages from oligonucleotide-based drugs, including targeted gene modulation and disease-specific interventions.

Supply chain complexity during phosphoramidite sourcing and the technical requirements for synthesis optimization and purification processes may limit accessibility among smaller research groups and developing regions with limited infrastructure for advanced oligonucleotide synthesis and quality verification systems.

Segmental Analysis

The market is segmented by product, application, end-use, and region. By product, the market is divided into services, oligonucleotides, reagents, equipment/synthesizer, and others. By application, the market is divided into PCR primers, sequencing, antisense oligonucleotides, DNA microarrays, PCR assays & panels, FISH, and others.

By end-use, the market is divided into academic research institutes, pharmaceutical & biotechnology companies, and diagnostic laboratories. Regionally, the market is divided into Asia Pacific, North America, Europe, Latin America, and Middle East & Africa.

By Product, Which Category Dominates in the Oligonucleotide Synthesis Market?

The services segment represents the dominant force in the oligonucleotide synthesis market, capturing approximately 32.6% of the total market share in 2025. This category encompasses solutions featuring critical custom synthesis functionality for research laboratories, pharmaceutical development, and diagnostic applications, including gene synthesis services, primer design support, and oligonucleotide manufacturing that enable flexible ordering, rapid turnaround, and comprehensive quality assurance across all molecular biology applications.

The services segment's market leadership stems from its essential role in research operations, with contract synthesis services capable of meeting diverse sequence requirements while maintaining cost-effective project economics and operational convenience across all research environments. Within the services segment, pharmaceutical development applications account for the largest revenue share, driven by extensive therapeutic oligonucleotide development programs and continuous drug discovery initiatives across global pharmaceutical operations.

The oligonucleotides segment maintains a substantial 26.4% market share, serving researchers and pharmaceutical companies who require ready-made oligonucleotide products, standard primer sequences, and catalogue offerings across routine molecular biology, diagnostic kit manufacturing, and high-throughput screening applications.

Oligonucleotides offer convenient access to commonly used sequences and immediate availability while providing sufficient quality standards to meet research demands and experimental requirements. The reagents segment accounts for 19.7% of the market, the equipment/synthesizer segment represents 13.8%, and others accounts for 7.5%, serving specialized synthesis needs, automated platform requirements, and complementary product categories.

Key advantages driving the services segment include:

• Established outsourcing infrastructure with integrated synthesis facilities that reduce capital investment complexity and ensure consistent product delivery
• Critical customization functionality allowing unlimited sequence design across different applications without equipment ownership penalties
• Proven quality assurance, delivering reliable synthesis fidelity while maintaining competitiveness against in-house synthesis alternatives
• Broad research acceptance enabling straightforward ordering protocols and quality standards across multiple scientific disciplines

Which Application Category Leads the Oligonucleotide Synthesis Market?

The PCR primers segment captures 33.1% of the oligonucleotide synthesis market in 2025, representing the most widely adopted application category across molecular biology research operations. This application sector offers high-volume consumption patterns, routine experimental usage, and fundamental research requirements that align with standard molecular biology specifications.

The PCR primers segment's dominance reflects its widespread adoption in gene amplification, cloning procedures, and diagnostic assay development where oligonucleotide primers provide essential DNA amplification initiation and sequence-specific targeting capabilities.

The sequencing segment maintains a 22.5% market share, serving genomics centers and pharmaceutical researchers requiring sequencing primers, next-generation sequencing library preparation, and Sanger sequencing applications across genome analysis, variant detection, and quality control operations.

These application categories provide comprehensive DNA analysis capabilities for research and clinical diagnostics. The antisense oligonucleotides segment accounts for 14.9% of the market, serving pharmaceutical developers requiring gene silencing therapeutics and RNA-targeting drug candidates.

The DNA microarrays segment represents 11.3%, PCR assays & panels accounts for 9.7%, FISH represents 5.6%, and others accounts for 2.9%, serving diverse specialized applications including gene expression analysis, molecular diagnostics, and cytogenetic research.

Who are the Primary End-Users of Oligonucleotide Synthesis Products?

Academic research institutes represent 37.2% of the oligonucleotide synthesis market in 2025, driven by extensive basic research programs, government funding availability, and comprehensive molecular biology investigation across university laboratories and research centers. This end-use category encompasses biology departments, genomics institutes, and medical research centers requiring diverse oligonucleotide products for fundamental research, grant-funded projects, and scientific investigation.

The academic research institutes segment's market leadership reflects its central role in biological research, with university laboratories providing sustained oligonucleotide demand and driving methodological innovation through scientific exploration.

The pharmaceutical & biotechnology companies segment accounts for 34.4% of the market, serving drug developers and biotech firms requiring therapeutic oligonucleotide development, diagnostic assay creation, and pharmaceutical research across drug discovery pipelines and clinical development programs.

These organizations provide substantial research investment for commercial product development and intellectual property generation. The diagnostic laboratories segment represents 28.4% market share, serving clinical testing facilities, molecular diagnostic companies, and pathology laboratories where oligonucleotides support disease detection, genetic screening, and patient diagnosis across healthcare delivery systems.

What are the Drivers, Restraints, and Key Trends of the Oligonucleotide Synthesis Market?

The market is driven by three concrete demand factors tied to pharmaceutical development and research advancement. First, increasing oligonucleotide therapeutic approvals and clinical pipeline growth creates growing demand for synthesis services, with global antisense drug development expanding by 15-20% annually in major pharmaceutical markets worldwide, requiring comprehensive GMP synthesis infrastructure. Second, expanding next-generation sequencing adoption and genomics research drives increased utilization of custom primers and sequencing oligonucleotides, with many research institutions implementing comprehensive sequencing programs for genomic investigation by 2030. Third, technological advancements in chemical modification techniques and high-throughput synthesis enable more effective and efficient oligonucleotide production that reduces manufacturing costs while improving therapeutic properties and nuclease resistance capabilities.

Market restraints include fluctuating phosphoramidite costs for synthesis reagents that can deter service providers from maintaining competitive pricing strategies, particularly in regions where specialty chemical costs and supply chain logistics face volatility pressures or availability constraints. Regulatory compliance complexity and GMP manufacturing requirements pose another significant challenge, as therapeutic oligonucleotide production demands stringent quality standards and comprehensive documentation, potentially causing increased operational expenditures and facility investment. Intellectual property constraints and licensing requirements create additional market challenges for therapeutic development, demanding ongoing investment in patent navigation and freedom-to-operate analysis improvements.

Key trends indicate accelerated oligonucleotide therapeutic development in Asia Pacific markets, particularly China and India, where contract manufacturing growth and pharmaceutical investment drive comprehensive synthesis capacity implementation. Technology integration trends toward automated synthesis platforms with increased throughput capabilities, modified nucleotide incorporation with enhanced stability profiles, and AI-driven sequence optimization enable improved manufacturing approaches that reduce production timelines and enhance therapeutic efficacy. However, the market thesis could face disruption if significant advances in peptide therapeutics or major shifts in drug modality preferences reduce reliance on traditional oligonucleotide-based therapeutic approaches.

Analysis of the Oligonucleotide Synthesis Market by Key Countries

Country	CAGR (2025-2035)
India	14.2%
China	13.8%
USA	12.5%
Japan	11.9%
Germany	10.7%
UK	10.1%
Canada	9.4%

The oligonucleotide synthesis market is expanding rapidly, with India leading at a 14.2% CAGR through 2035, driven by rapid oligonucleotide manufacturing expansion in Hyderabad biotech clusters, growing contract research services, and comprehensive pharmaceutical development infrastructure. China follows at 13.8%, supported by heavy investments in biotechnology research, expanding genomics capabilities, and accelerated pharmaceutical innovation initiatives.

USA records 12.5%, reflecting oligonucleotide-based therapeutic approvals and increasing precision medicine capabilities. Japan posts 11.9%, anchored by strong sequencing market presence and molecular diagnostics industry operations. Germany grows at 10.7%, with government-backed genetic research programs and advanced pharmaceutical development. UK advances at 10.1%, emphasizing academic genomics commercialization and biotechnology translation, while Canada grows steadily at 9.4%, focusing on personalized medicine adoption through healthcare innovation programs and genomics research.

India Leads Global Market Expansion

India demonstrates the strongest growth potential in the oligonucleotide synthesis market with a CAGR of 14.2% through 2035. The country's leadership position stems from rapid contract manufacturing expansion in Hyderabad and Bangalore biotech clusters, growing pharmaceutical research investment, and comprehensive oligonucleotide production infrastructure enabling mainstream synthesis service adoption.

Growth is concentrated in major biotechnology hubs, including Hyderabad, Bangalore, Pune, and Ahmedabad, where biotech parks and expanding synthesis infrastructure are implementing large-scale oligonucleotide manufacturing for pharmaceutical development and research service applications.

Distribution channels through contract research organizations, direct pharmaceutical partnerships, and international export networks expand deployment across global pharmaceutical companies and research institutions. The country's growing biotechnology sector provides momentum for synthesis services, including cost-competitive manufacturing advantages supporting international outsourcing.

Key market factors:

• Contract manufacturing demand concentrated in biotech clusters and pharmaceutical development zones with comprehensive synthesis networks
• Infrastructure development through biotech park expansion and GMP facility improvements
• Comprehensive service ecosystem, including established contract research capabilities with proven quality systems
• Technology integration featuring automated synthesis platforms, purification systems, and quality control technologies

China Emerges as Research Investment Leader

In major research centers including Beijing, Shanghai, Shenzhen, and Hangzhou, the development and utilization of oligonucleotide synthesis services is accelerating across pharmaceutical research operations and genomics investigation segments, driven by government biotechnology investment and comprehensive research infrastructure programs. The market demonstrates strong growth momentum with a CAGR of 13.8% through 2035, linked to national biotechnology development policies, expanding pharmaceutical research infrastructure, and sustained genomics research funding.

Chinese research institutions are implementing advanced oligonucleotide technologies and custom synthesis services to enhance research capabilities while meeting growing demand in expanding pharmaceutical sectors and genomics industries. The country's biotechnology emphasis creates persistent demand for synthesis services, while increasing focus on indigenous innovation drives adoption of domestic oligonucleotide production systems.

Key development areas:

• Pharmaceutical research and genomics institutes leading oligonucleotide synthesis adoption with comprehensive research programs
• Integrated biotechnology networks providing efficient service delivery with extensive research collaboration infrastructure
• Technology partnerships between international synthesis companies and Chinese research institutions are expanding market reach
• Integration of automated synthesis systems and comprehensive quality management protocols

USA Shows Therapeutic Approval Leadership

USA’s market expansion is driven by oligonucleotide therapeutic approvals, including antisense drug commercialization in Massachusetts and California biotech hubs, and expanding precision medicine implementations across multiple pharmaceutical regions. The country demonstrates solid growth potential with a CAGR of 12.5% through 2035, supported by established pharmaceutical infrastructure, advanced biotechnology sector, and growing integration with RNA therapeutic technologies across drug development pipelines.

Pharmaceutical companies face expanding development programs related to oligonucleotide drugs and personalized medicine, creating investment in GMP synthesis facilities and support from specialized contract manufacturers. However, growing therapeutic approvals and established research capacity create compelling business cases for oligonucleotide synthesis adoption, particularly in biotech regions where nucleic acid therapeutics have a direct impact on drug development portfolios.

Key market characteristics:

• Pharmaceutical development and biotechnology segments showing fastest growth with substantial increase in therapeutic oligonucleotide requirements
• Regional expansion trends focused on biotech clusters in Massachusetts, California, and Mid-Atlantic states
• Future projections indicate the need for expanded GMP capacity and advanced synthesis technology development programs
• Growing emphasis on therapeutic development and regulatory compliance positioning in USApharmaceutical markets

Japan Demonstrates Sequencing Market Strength

The Japanese market leads in sequencing applications based on integration with molecular diagnostics excellence and genomics research infrastructure for enhanced healthcare outcomes. The country shows robust potential with a CAGR of 11.9% through 2035, driven by advanced healthcare system, strong diagnostics industry, and the expansion of genomics research facilities in major research centers, including Tokyo, Osaka, Kyoto, and Yokohama.

Research institutions are adopting advanced oligonucleotide synthesis services for sequencing primer production and diagnostic assay development, particularly in regions with sophisticated research requirements and specialized molecular biology demands requiring comprehensive quality standards. Technology deployment channels through established research supply distributors and pharmaceutical partnerships expand coverage across university laboratories and diagnostic companies.

Leading market segments:

• Sequencing centers and molecular diagnostics companies in major research hubs implementing comprehensive oligonucleotide programs
• Strategic partnerships with synthesis service providers, achieving stringent quality specifications and delivery standards
• Collaborative research between academic institutions and diagnostic companies are expanding application capabilities
• Focus on precision diagnostics initiatives and genomic medicine methodologies

Germany Emphasizes Government-Backed Research

In major research regions including Bavaria, North Rhine-Westphalia, and Baden-Württemberg, university laboratories and pharmaceutical research centers are implementing comprehensive oligonucleotide utilization strategies to optimize genetic research and advance therapeutic development, with documented research programs showing significant innovation output through government funding integration and academic-industry collaboration techniques.

The market shows steady growth potential with a CAGR of 10.7% through 2035, linked to government research funding infrastructure, established pharmaceutical research capabilities, and ongoing genomics investigation requirements in major research regions. German researchers are adopting proven oligonucleotide synthesis services and custom sequence protocols to enhance research productivity while maintaining quality standards demanded by scientific publications and pharmaceutical development specifications. The country's research excellence culture creates persistent demand for high-quality oligonucleotide supply and synthesis services that integrate with rigorous scientific standards.

Market development factors:

• Academic research institutes and pharmaceutical companies leading oligonucleotide synthesis adoption across Germany
• Government research funding and biotechnology initiatives providing support for genomics development
• Strategic relationships between German researchers and international synthesis providers are expanding service capabilities
• Emphasis on research quality and scientific rigor across molecular biology segments

UK Shows Academic Commercialization Focus

UK's oligonucleotide synthesis market demonstrates competitive positioning focused on academic genomics commercialization and biotechnology translation integration, with documented spin-out company formation, achieving research commercialization through university technology transfer in Cambridge, Oxford, and London research clusters.

The country maintains moderate growth momentum with a CAGR of 10.1% through 2035, driven by strong academic research base, established biotechnology sector, and strategic emphasis on research translation. Major research institutions, including operations in university genomics centers and biotech innovation hubs, showcase expanding oligonucleotide implementations where synthesis services support research programs and comprehensive technology development initiatives.

Key market characteristics:

• Academic institutions and biotechnology startups driving oligonucleotide demand with emphasis on research translation and commercial development
• Innovation partnerships enabling research commercialization with comprehensive technology transfer programs
• Technology collaboration between UK universities and synthesis service companies is expanding market capabilities
• Emphasis on translational research and biotechnology entrepreneurship methodologies

Canada Demonstrates Personalized Medicine Growth

Canada's oligonucleotide synthesis market demonstrates growth-focused landscape, characterized by personalized medicine program integration with healthcare innovation operations across genomics research, diagnostic development, and precision therapy applications. The country shows steady growth momentum with a CAGR of 9.4% through 2035, driven by healthcare innovation investment and genomics research emphasis in research facilities concentrated in Ontario, Quebec, and British Columbia.

Canada's focus on precision medicine and genomics integration creates requirements for oligonucleotide products that support comprehensive research initiatives and healthcare applications in academic and clinical operations. The market benefits from partnerships between research institutions and synthesis providers, creating research supply ecosystems that prioritize quality reliability and research support. Research facilities in major academic centers showcase established oligonucleotide implementations where synthesis services achieve research requirements through integrated supply programs.

Key market characteristics:

• Research institutes and healthcare organizations driving oligonucleotide requirements with emphasis on personalized medicine and genomics applications
• Healthcare innovation partnerships enabling research advancement with comprehensive funding programs
• Regional collaboration between Canadian researchers and synthesis service providers is expanding capabilities
• Emphasis on precision healthcare and genomics integration methodologies

Europe Market Split by Country

The oligonucleotide synthesis market in Europe is projected to grow from USD 1.24 billion in 2025 to USD 3.89 billion by 2035, registering a CAGR of 12.1% over the forecast period. Germany is expected to maintain its leadership position with a 28.9% market share in 2025, supported by its advanced pharmaceutical research infrastructure, comprehensive genomics research programs, and strong biotechnology industry across major research centers.

UK follows with a 24.7% share in 2025, driven by established academic research excellence and integrated biotechnology commercialization networks. France holds a 19.3% share in 2025 through its pharmaceutical research capabilities and genomics institute presence. Switzerland commands a 15.6% share, while rest of Europe accounts for 11.5% in 2025.

By 2035, Germany is projected to hold 28.6% share, UK 24.9%, France 19.5%, Switzerland 15.4%, and rest of Europe 11.6%, reflecting sustained growth momentum across all major European markets and increasing oligonucleotide synthesis adoption in diversified research applications implementing comprehensive pharmaceutical development programs.

Competitive Landscape of the Oligonucleotide Synthesis Market

The oligonucleotide synthesis market features approximately 30-40 meaningful players with moderate concentration, where the top three companies control roughly 40-50% of global market presence through established synthesis capabilities and extensive customer relationships across pharmaceutical and research sectors.

Market leaders include Thermo Fisher Scientific, Merck KGaA, and Danaher, which maintain competitive advantages through comprehensive oligonucleotide synthesis portfolios, global service networks, and deep expertise in the life sciences tools and pharmaceutical services sectors, creating strong customer relationships among pharmaceutical companies and research institutions.

These companies leverage established manufacturing facilities and ongoing technology innovation initiatives to defend market positions while expanding into adjacent therapeutic oligonucleotide manufacturing applications and synthetic biology markets. Thermo Fisher Scientific Inc. commands a 17.4% market share through integrated synthesis services and strategic positioning in global life sciences markets.

Challengers encompass Revvity Discovery Limited, Agilent Technologies, Inc., and Twist Bioscience, which compete through specialized service portfolios and strong regional presence in key research markets. Specialty providers, including Bio-Synthesis Inc., Kaneka Eurogentec S.A., LGC Biosearch Technologies, and Biolegio, focus on specific geographical regions or application segments, offering differentiated capabilities in custom synthesis services, modified oligonucleotides, and technical support services.

Regional players and emerging synthesis companies create competitive pressure through innovative technologies and strategic market positioning, particularly in high-growth markets including China and India, where local presence provides advantages in cost competitiveness and customer proximity.

Market dynamics favor companies that combine synthesis quality with comprehensive service capabilities that address the complete value chain from sequence design through synthesis execution and quality verification. Strategic investments in GMP manufacturing and therapeutic oligonucleotide capabilities enable service differentiation and market leadership across pharmaceutical applications.

Global Oligonucleotide Synthesis Market - Stakeholder Contribution Framework

Oligonucleotide synthesis products represent a critical life sciences technology that enables pharmaceutical researchers, molecular biologists, and diagnostic developers to obtain custom nucleic acid sequences and achieve research objectives without substantial infrastructure investment, typically providing essential sequence customization and quality assurance capabilities while supporting diverse scientific applications.

With the market projected to grow from USD 4.71 billion in 2025 to USD 16.5 billion by 2035 at a 13.4% CAGR, these services offer compelling advantages - unlimited sequence design, rapid turnaround, and guaranteed quality - making them essential for custom synthesis services (largest segment), PCR primer applications (dominant category), and diverse research applications seeking reliable oligonucleotide supply. Scaling service capacity and market development requires coordinated action across biotechnology policy, quality standards, synthesis providers, pharmaceutical companies, and research institutions.

How Governments Could Spur Local Production and Adoption?

• Biotechnology Development Programs: Include oligonucleotide synthesis capabilities in national biotechnology strategies, providing targeted funding for GMP facilities in regions with pharmaceutical infrastructure and supporting local contract manufacturers through investment incentives and technology development support.
• Research Policy & Innovation Support: Implement comprehensive frameworks for genomics research funding, provide grants for oligonucleotide therapeutic development, and establish quality standards that support pharmaceutical manufacturing advancement.
• Trade Policy & Market Access: Create balanced import-export frameworks across pharmaceutical services and research products, establish harmonized regulatory practices for oligonucleotide therapeutics, and develop international cooperation protocols that facilitate contract manufacturing and quality recognition.
• Skills Development & Training: Fund biotechnology education programs, molecular biology training, and pharmaceutical manufacturing courses. Invest in technology transfer initiatives that bridge synthesis providers with pharmaceutical companies and research institutions.

How Industry Bodies Could Support Market Development?

• Quality Standards & Certification: Define standardized performance specifications for oligonucleotide synthesis across research, diagnostic, and therapeutic applications, establish universal testing protocols and purity metrics, and create GMP certification programs for pharmaceutical manufacturing that companies can implement.
• Market Education & Best Practices: Lead communication initiatives that demonstrate oligonucleotide synthesis value, emphasizing proven quality assurance, turnaround reliability, and application versatility compared to in-house synthesis alternatives and conventional approaches.
• Regulatory Guidance Standards: Develop pharmaceutical manufacturing recommendations for therapeutic oligonucleotides, comprehensive quality control protocols, and regulatory compliance best practices, ensuring appropriate manufacturing standards across different therapeutic modalities and clinical applications.

How Manufacturers and Technology Players Could Strengthen the Ecosystem?

• Synthesis Technology Development: Develop next-generation automated platforms with enhanced throughput capabilities, advanced modification chemistries with expanded functionality, and quality-specific features that improve synthesis efficiency while optimizing production economics and product quality.
• Service Support Platforms: Provide comprehensive customer support that integrates sequence design assistance, application consulting, quality documentation, and technical troubleshooting, enabling customers to maximize experimental success and research productivity.
• Supply Chain Integration: Offer flexible service arrangements for pharmaceutical companies and research institutions, including long-term supply agreements, dedicated synthesis capacity, and collaborative development programs that keep oligonucleotide supply aligned with project requirements and quality standards.

Key Players in the Oligonucleotide Synthesis Market

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher Corporation
• Revvity Discovery Limited
• Agilent Technologies, Inc.
• Bio-Synthesis Inc.
• Kaneka Eurogentec S.A.
• LGC Biosearch Technologies
• Biolegio B.V.
• Twist Bioscience Corporation

Scope of the Report

Items	Values
Quantitative Units	USD 4.71 Billion
Product	Services, Oligonucleotides, Reagents, Equipment/Synthesizer, Others
Application	PCR Primers, Sequencing, Antisense Oligonucleotides, DNA Microarrays, PCR Assays & Panels, FISH, Others
End-Use	Academic Research Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories
Regions Covered	Asia Pacific, North America, Europe, Latin America, Middle East & Africa
Country Covered	India, China, USA, Japan, Germany, UK, Canada, and 40+ countries
Key Companies Profiled	Thermo Fisher Scientific, Merck KGaA, Danaher, Revvity Discovery Limited, Agilent Technologies, Inc., Bio-Synthesis, Inc., Kaneka Eurogentec S.A., LGC Biosearch Technologies, Biolegio, Twist Bioscience
Additional Attributes	Dollar sales by product categories, regional research trends across Asia Pacific, North America, and Europe, competitive landscape with synthesis service providers and pharmaceutical suppliers, quality specifications and synthesis requirements, integration with pharmaceutical development operations and research facilities.

Oligonucleotide Synthesis Market by Segments

• Product :

  • Services
  • Oligonucleotides
  • Reagents
  • Equipment/Synthesizer
  • Others

• Application :

  • PCR Primers
  • Sequencing
  • Antisense Oligonucleotides
  • DNA Microarrays
  • PCR Assays & Panels
  • FISH
  • Others

• End-Use :

  • Academic Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories

• Region :

  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • ASEAN
    • Rest of Asia Pacific
  • North America
    • USA
    • Canada
    • Mexico
  • Europe
    • Russia
    • Germany
    • Norway
    • France
    • Rest of Europe
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Rest of Middle East & Africa